Literature DB >> 15998681

Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents.

Aloke V Finn1, Frank D Kolodgie, Jan Harnek, L J Guerrero, Eduardo Acampado, Kirubel Tefera, Kristi Skorija, Deena K Weber, Herman K Gold, Renu Virmani.   

Abstract

BACKGROUND: Although effective coverage of challenging coronary lesions has warranted the use of overlapping drug-eluting stents, the histopathological response to stent overlap is unknown. METHODS AND
RESULTS: The arterial reaction to overlapping Cypher or Taxus drug-eluting stents was examined in rabbits with bare metal stents, BxVelocity or Express, serving as controls. Single iliac artery balloon injury was followed by placement of 2 overlapping 3.0-mm-diameter drug-eluting stents or bare metal stents in 60 animals (mean length of overlap, 9.8+/-3.6 mm). Stented arteries were harvested at 28 and 90 days for histology. Overlapped segments exhibited delayed healing compared with proximal and distal nonoverlapping sites at 28 days. Overlapped segments in Taxus stents induced significantly more luminal heterophils/eosinophils and fibrin deposition than Cypher; peristrut giant cell infiltration, however, was more frequent in the latter. Overlapping bare metal stents also showed mild delayed healing compared with nonoverlapped segments, but not to the same extent as drug-eluting stents. Although neointimal thickness within the overlap was similar in 28- and 90-day Cypher stents, there was a significant increase with Taxus (P=0.03).
CONCLUSIONS: Compared with bare metal stents, drug-eluting stents further delay arterial healing and promote inflammation at sites of overlap. Taxus stents induced greater fibrin deposition, medial cell loss, heterophils/eosinophils, and late neointimal hyperplasia. Patients receiving overlapping drug-eluting stents need more frequent follow-up than patients with nonoverlapping stents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15998681     DOI: 10.1161/CIRCULATIONAHA.104.508937

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  76 in total

1.  Interventional cardiology: does stent overlap make a difference to clinical outcome?

Authors:  Antonio Colombo; Rasha Al-Lamee
Journal:  Nat Rev Cardiol       Date:  2010-07       Impact factor: 32.419

2.  Drug deposition in coronary arteries with overlapping drug-eluting stents.

Authors:  Farhad Rikhtegar; Elazer R Edelman; Ufuk Olgac; Dimos Poulikakos; Vartan Kurtcuoglu
Journal:  J Control Release       Date:  2016-07-16       Impact factor: 9.776

3.  Sustained Efficacy and Arterial Drug Retention by a Fast Drug Eluting Cross-Linked Fatty Acid Coronary Stent Coating.

Authors:  Natalie Artzi; Abraham R Tzafriri; Keith M Faucher; Geoffrey Moodie; Theresa Albergo; Suzanne Conroy; Scott Corbeil; Paul Martakos; Renu Virmani; Elazer R Edelman
Journal:  Ann Biomed Eng       Date:  2015-08-28       Impact factor: 3.934

4.  Paclitaxel induces thrombomodulin downregulation in human aortic endothelial cells.

Authors:  Huang-Joe Wang; Te-Ling Lu; Haimei Huang; Huey-Chun Huang
Journal:  Tex Heart Inst J       Date:  2011

5.  Advantages and disadvantages of biodegradable platforms in drug eluting stents.

Authors:  Agustina Rodriguez-Granillo; Bibiana Rubilar; Gaston Rodriguez-Granillo; Alfredo E Rodriguez
Journal:  World J Cardiol       Date:  2011-03-26

6.  Late thrombosis with drug-eluting stents: anatomy of a controversy and lessons learned.

Authors:  Steven E Nissen
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

7.  Vascular pathology as a result of drug-eluting stents.

Authors:  Martin R Bennett
Journal:  Heart       Date:  2007-08       Impact factor: 5.994

Review 8.  The risk of drug-eluting stent thrombosis with noncardiac surgery.

Authors:  Emmanouil S Brilakis; Subhash Banerjee; Peter B Berger
Journal:  Curr Cardiol Rep       Date:  2007-09       Impact factor: 2.931

9.  Use of a novel anti-proliferative compound coated on a biopolymer to mitigate platelet-derived growth factor-induced proliferation in human aortic smooth muscle cells: comparison with sirolimus.

Authors:  Yong-Dan Tang; Ambarish Pandey; Antonina Kolmakova; Xin-Tong Wang; Subbu S Venkatraman; Subroto Chatterjee; Freddy Y C Boey
Journal:  Glycoconj J       Date:  2008-10-14       Impact factor: 2.916

Review 10.  Pathology of atherosclerosis and stenting.

Authors:  Frank D Kolodgie; Gaku Nakazawa; Giuseppe Sangiorgi; Elena Ladich; Allen P Burke; Renu Virmani
Journal:  Neuroimaging Clin N Am       Date:  2007-08       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.